Edgewise Therapeutics (EWTX) Liabilities and Shareholders Equity (2020 - 2026)

Edgewise Therapeutics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $518.5 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $518.5 million, up 14.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 14.3% YoY), and the FY2025 annual result was $552.6 million, up 13.51% from the prior year.
• Liabilities and Shareholders Equity came in at $518.5 million for Q1 2026 at Edgewise Therapeutics, down from $552.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $613.3 million in Q2 2025 to a low of $257.4 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $454.4 million (2025), against an average of $435.8 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 64.21% in 2024 and declined 17.95% in 2025, its largest moves.
• Edgewise Therapeutics' Liabilities and Shareholders Equity stood at $367.1 million in 2022, then fell by 7.37% to $340.0 million in 2023, then jumped by 43.17% to $486.8 million in 2024, then advanced by 13.51% to $552.6 million in 2025, then slipped by 6.17% to $518.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $518.5 million (Q1 2026), $552.6 million (Q4 2025), and $583.5 million (Q3 2025), per Business Quant data.